Vijay Satyanand Pande bought $4.3M of BIOA
director at BioAge Labs, Inc.. 219,195 shares at an average of $19.75, traded Oct 1, 2024, filed Oct 3, 2024.
Score components
- +15RoleDirector
- +25Trade size$4.3M at market
- +6Relative to holdingsHoldings up 24%
- 0Price contextNear the top of the 52-week range
- +15Cluster5 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.0%, 3m -73.3%, 6m -83.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-024688, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2024 | POpen-market purchase Common Stockindirect: Andreessen Horowitz LSV Fund III, L.P. | +126,793 | $19.73 | $2.5M | 1,026,793 | Oct 3, 2024 |
| Oct 2, 2024 | POpen-market purchase Common Stockindirect: Andreessen Horowitz LSV Fund III, L.P. | +67,096 | $19.73 | $1.3M | 1,093,889 | Oct 3, 2024 |
| Oct 3, 2024 | POpen-market purchase Common Stockindirect: Andreessen Horowitz LSV Fund III, L.P. | +25,306 | $19.90 | $504k | 1,119,195 | Oct 3, 2024 |
Related signals
Other insiders at BioAge Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $1.6M 62,566 shares | -148% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $157k 8,820 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $151k 7,433 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $139k 7,433 shares | -100% | |
| 40Moderate | BioAge Labs, Inc. | Dov A Goldstein Md Chief Financial Officer | $532k 27,000 shares | -55% | |
| 50Moderate | BioAge Labs, Inc. | Kristen Fortney Chief Executive Officer | $4.2M 233,107 shares | -19% | |
| 25Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $95k 7,433 shares | -100% | |
| 12Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $216k 18,000 shares | -100% | |
| 21Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $702k 68,897 shares | -100% | |
| 44Moderate | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $47k 2,632 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.